Cerliponase alfa: Interim Phase I/II data

Interim data from 9 patients ages 3-16 with late-infantile CLN2 disease in an open-label, dose-escalation, international Phase I/II trial showed that 30-300 mg BMN 190 every other week for >6 months a...